Extracts of Thesium chinense inhibit SARS-CoV-2 and inflammation in vitro.

IF 3.9 3区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Pharmaceutical Biology Pub Date : 2023-09-07 DOI:10.1080/13880209.2023.2253841

Juncheng Ma, Juanru Wei, Gang Chen, Xiaowei Yan, Hechun Sun, Ning Li

{"title":"Extracts of Thesium chinense inhibit SARS-CoV-2 and inflammation in vitro.","authors":"Juncheng Ma, Juanru Wei, Gang Chen, Xiaowei Yan, Hechun Sun, Ning Li","doi":"10.1080/13880209.2023.2253841","DOIUrl":null,"url":null,"abstract":"Context: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading rapidly. Relevant research based on the antiviral effects of Thesium chinense Turcz (Santalaceae) was not found.Objective: To investigate the antiviral and anti-inflammatory effects of extracts of T. chinense.Materials and methods: To investigate the anti-entry and replication effect of the ethanol extract of T. chinense (drug concentration 80, 160, 320, 640, 960 μg/mL) against the SARS-CoV-2. Remdesivir (20.74 μM) was used as positive control, and Vero cells were used as host cells to detect the expression level of nucleocapsid protein (NP) in the virus by real-time quantitative polymerase chain reaction (RT-PCR) and Western blotting. RAW264.7 cells were used as an anti-inflammatory experimental model under lipopolysaccharide (LPS) induction, and the expression levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were detected by enzyme-linked immunosorbent assay (ELISA).Results: The ethanol extract of T. chinense significantly inhibited the replication (half maximal effective concentration, EC50: 259.3 μg/mL) and entry (EC50: 359.1 μg/mL) of SARS-CoV-2 into Vero cells, and significantly reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells. Petroleum ether (EC50: 163.6 μg/mL), ethyl acetate (EC50: 22.92 μg/mL) and n-butanol (EC50: 56.8 μg/mL) extracts showed weak inhibition of SARS-CoV-2 replication in Vero cells, and reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells.Conclusion: T. chinense can be a potential candidate to fight SARS-CoV-2, and is becoming a traditional Chinese medicine candidate for treating COVID-19.","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"61 1","pages":"1446-1453"},"PeriodicalIF":3.9000,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486283/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13880209.2023.2253841","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading rapidly. Relevant research based on the antiviral effects of Thesium chinense Turcz (Santalaceae) was not found.

Objective: To investigate the antiviral and anti-inflammatory effects of extracts of T. chinense.

Materials and methods: To investigate the anti-entry and replication effect of the ethanol extract of T. chinense (drug concentration 80, 160, 320, 640, 960 μg/mL) against the SARS-CoV-2. Remdesivir (20.74 μM) was used as positive control, and Vero cells were used as host cells to detect the expression level of nucleocapsid protein (NP) in the virus by real-time quantitative polymerase chain reaction (RT-PCR) and Western blotting. RAW264.7 cells were used as an anti-inflammatory experimental model under lipopolysaccharide (LPS) induction, and the expression levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were detected by enzyme-linked immunosorbent assay (ELISA).

Results: The ethanol extract of T. chinense significantly inhibited the replication (half maximal effective concentration, EC₅₀: 259.3 μg/mL) and entry (EC₅₀: 359.1 μg/mL) of SARS-CoV-2 into Vero cells, and significantly reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells. Petroleum ether (EC₅₀: 163.6 μg/mL), ethyl acetate (EC₅₀: 22.92 μg/mL) and n-butanol (EC₅₀: 56.8 μg/mL) extracts showed weak inhibition of SARS-CoV-2 replication in Vero cells, and reduced the levels of IL-6 and TNF-α produced by LPS-stimulated RAW264.7 cells.

Conclusion: T. chinense can be a potential candidate to fight SARS-CoV-2, and is becoming a traditional Chinese medicine candidate for treating COVID-19.

Abstract Image

查看原文本刊更多论文

中国梧桐提取物体外抑制SARS-CoV-2和炎症。

背景:严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)仍在快速传播。目前，尚没有相关的研究基于桑草科植物Thesium chinense Turcz抗病毒作用。目的:研究黄芪提取物的抗病毒和抗炎作用。材料与方法:研究三叶草乙醇提取物(药物浓度分别为80、160、320、640、960 μg/mL)对SARS-CoV-2的抗进入和复制作用。以Remdesivir (20.74 μM)为阳性对照，以Vero细胞为宿主细胞，采用实时定量聚合酶链反应(RT-PCR)和Western blotting检测病毒核衣壳蛋白(NP)的表达水平。将RAW264.7细胞作为脂多糖(LPS)诱导下的抗炎实验模型，采用酶联免疫吸附法(ELISA)检测其肿瘤坏死因子-α (TNF-α)和白细胞介素-6 (IL-6)的表达水平。结果:三叶草乙醇提取物显著抑制SARS-CoV-2复制(最大有效浓度的一半，EC50: 259.3 μg/mL)和进入Vero细胞(EC50: 359.1 μg/mL)，显著降低lps刺激RAW264.7细胞产生的IL-6和TNF-α水平。石油醚(EC50: 163.6 μg/mL)、乙酸乙酯(EC50: 22.92 μg/mL)和正丁醇(EC50: 56.8 μg/mL)提取物对Vero细胞的SARS-CoV-2复制有较弱的抑制作用，并降低lps刺激RAW264.7细胞产生的IL-6和TNF-α水平。结论:中华弓形虫可能是抗SARS-CoV-2的潜在候选药物，并正在成为治疗COVID-19的候选中药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Biology 医学-药学

CiteScore

6.70

自引率

2.60%

发文量

191

审稿时长

1 months

期刊介绍： Pharmaceutical Biology will publish manuscripts describing the discovery, methods for discovery, description, analysis characterization, and production/isolation (including sources and surveys) of biologically-active chemicals or other substances, drugs, pharmaceutical products, or preparations utilized in systems of traditional medicine. Topics may generally encompass any facet of natural product research related to pharmaceutical biology. Papers dealing with agents or topics related to natural product drugs are also appropriate (e.g., semi-synthetic derivatives). Manuscripts will be published as reviews, perspectives, regular research articles, and short communications. The primary criteria for acceptance and publication are scientific rigor and potential to advance the field.